A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose-ranging, Parallel Group Study To Evaluate Safety And Efficacy Of Pf-04937319 And Sitagliptin On Glycemic Control In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Phase of Trial: Phase II
Latest Information Update: 03 Feb 2017
At a glance
- Drugs PF 4937319 (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Aug 2012 Planned End Date changed from 1 Dec 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 16 Jul 2012 New source identified and integrated (Clinical Trials Registry - India: CTRI2012-07-002798).